A Hidden Tipping Point in Alzheimer’s May Explain Why Some Stay Sharp

When you hear the word Alzheimer’s, the first thing that comes to mind is usually a steady march toward memory loss. Yet many older people carry the classic amyloid‑β plaques and tangled tau proteins in their brains and never show any signs of dementia. A new international study set out to understand why.

Scientists from the Vlaams Instituut voor Biotechnologie (VIB), KU Leuven, the UK Dementia Research Institute and the biotech firm Muna Therapeutics examined donated brain tissue from three groups: older adults with cognitive decline, age‑matched peers who remained cognitively healthy, and a handful of centenarians who had lived past 100 with their minds still intact. Using cutting‑edge spatial transcriptomics and single‑cell sequencing, they could watch how individual cells behaved in their native tissue context.

The picture that emerged placed microglia—the brain’s resident immune cells—right at the centre of the story. Early in the disease process, microglia adopt an inflammatory stance that hugs amyloid plaques. Later, as tau pathology spreads, the same cells flip into an antigen‑presenting mode, a shift that coincides with neuronal loss and the onset of dementia.

What’s striking is that this transition does not happen the same way for everyone. In people in their 80s who had lots of plaques but no dementia, microglia stayed locked in the early inflammatory state and never progressed to the later, potentially harmful mode. By contrast, many centenarians showed the antigen‑presenting signature, but it appeared without the accompanying tau buildup, suggesting their brains somehow uncoupled the dangerous immune response from neurodegeneration.

“We’ve essentially caught a biological ‘fork in the road’,” says Professor Bart De Strooper, one of the senior authors. “Understanding which side of that fork a brain takes could open up entirely new therapeutic strategies.”

For drug developers, the findings hint that timing may be everything. Rather than concentrating solely on clearing plaques—a strategy that has produced mixed results in clinical trials—future medicines might aim to preserve the beneficial early microglial activity or gently steer the cells away from the later antigen‑presenting state. Molecules such as TREM2, which help regulate microglial transitions, are already on researchers’ radar.

“If we can prolong the window where microglia are protective, we might extend cognitive resilience well into old age,” adds Professor Mark Fiers, co‑senior author. The hope is that by targeting the immune response, we could delay or even prevent the cascade that turns Alzheimer’s pathology into debilitating dementia.